Yuelie Lu

US Patent:

6921762, Jul 26, 2005

Filed:

Nov 15, 2002

Appl. No.:

10/298205

Inventors:

Guolin Cai - Thousand Oaks CA, US
Jennifer N. Chau - Santa Ana CA, US
Celia Dominguez - Thousand Oaks CA, US
Yuelie Lu - Thousand Oaks CA, US
Gilbert M. Rishton - Malibu CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D487/04
C07D471/04
A61K031/4188

US Classification:

514249, 51425216, 5142591, 5142595, 544263, 544281

Abstract:

Selected novel substituted indolizine-like compounds are effective for treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

7687643, Mar 30, 2010

Filed:

Dec 15, 2004

Appl. No.:

11/014184

Inventors:

Andrew Tasker - Simi Valley CA, US
Shawn Eisenberg - Oxnard CA, US
Yuelie Lu - Belle Mead NJ, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 209/40

US Classification:

548530, 546201

Abstract:

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

8278280, Oct 2, 2012

Filed:

Apr 8, 2008

Appl. No.:

12/082219

Inventors:

Gordon Ng - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Colin V. Gegg - Newbury Park CA, US
Thomas Storz - Warwick NY, US
Yuelie Lu - Belle Mead NJ, US
Derin C. D'Amico - Newbury Park CA, US
Mark A. Jarosinski - Fishers IN, US
Qi Huang - Moorpark CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 7/18

US Classification:

514 216, 514 125, 514 214, 514 215, 530314, 530326, 530328

Abstract:

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

US Patent:

8288351, Oct 16, 2012

Filed:

Apr 8, 2008

Appl. No.:

12/082224

Inventors:

Gordon Ng - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Colin V. Gegg - Newbury Park CA, US
Thomas Storz - Warwick NY, US
Yuelie Lu - Belle Mead NJ, US
Derin C. D'Amico - Newbury Park CA, US
Mark A. Jarosinski - Fishers IN, US
Qi Huang - Moorpark CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 7/18

US Classification:

514 216, 514 125, 514 214, 514 215, 530314, 530326, 530328

Abstract:

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

US Patent:

20050215470, Sep 29, 2005

Filed:

Oct 21, 2004

Appl. No.:

10/972236

Inventors:

Gordon Ng - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Colin Gegg - Newbury Park CA, US
Benny Askew - Newbury Park CA, US
Thomas Storz - Thousand Oaks CA, US
Yuelie Lu - Thousand Oaks CA, US
Derin D'Amico - Newbury Park CA, US

International Classification:

A61K038/10
A61K038/08

US Classification:

514012000, 514013000, 514014000, 514015000, 514016000, 514017000

Abstract:

The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.

US Patent:

20090048149, Feb 19, 2009

Filed:

Apr 9, 2008

Appl. No.:

12/082395

Inventors:

Gordon Ng - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Colin V. Gegg - Newbury Park CA, US
Thomas Storz - Warwick NY, US
Yuelie Lu - Belle Mead NJ, US
Derin C. D'Amico - Newbury Park CA, US
Mark A. Jarosinski - Fishers IN, US
Qi Huang - Moorpark CA, US

International Classification:

A61K 38/08
A61K 38/02
A61P 29/00
A61P 25/00
A61P 11/06

US Classification:

514 2, 514 15

Abstract:

The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

US Patent:

62622706, Jul 17, 2001

Filed:

Aug 11, 1999

Appl. No.:

9/371172

Inventors:

Richard W. Draper - North Caldwell NJ
Radha V. Iyer - Edison NJ
Yuelie Lu - Thousand Oaks CA
Eugene J. Vater - Lyndhurst NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D40510
C07D40512

US Classification:

546196

Abstract:

A short practical commercial process for the efficient enantioselective synthesis of the non-steroidal antiestrogen of formula I or XIV ##STR1## or a pharmaceutically acceptable salt thereof.

US Patent:

20220411439, Dec 29, 2022

Filed:

Jun 16, 2020

Appl. No.:

17/618060

Inventors:

- San Diego CA, US
Evan W. ROGERS - San Diego CA, US
Yuelie LU - San Diego CA, US
Han ZHANG - San Diego CA, US
Jing LIU - San Diego CA, US

International Classification:

C07D 498/22
A61P 35/00

Abstract:

This disclosure relates to polymorphs of (3aR,11S,20aS)-7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.